Healthcare provider profile · identity verified

Tina Leanne Walker, M.D.

Family Practice · YORBA LINDA, CA · NPI 1871807784

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	240	80
Rosuvastatin Calcium	Rosuvastatin Calcium	190	58
Levothyroxine Sodium	Levothyroxine Sodium	163	49
Lisinopril	Lisinopril	158	49
Amlodipine Besylate	Amlodipine Besylate	143	51
Losartan Potassium	Losartan Potassium	143	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	123	20
Omeprazole	Omeprazole	98	37
Simvastatin	Simvastatin	98	31
Atenolol	Atenolol	91	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	75	23
Metformin Hcl Er	Metformin Hcl	72	26
Albuterol Sulfate Hfa	Albuterol Sulfate	70	28
Gabapentin	Gabapentin	67	25
Lorazepam	Lorazepam	61	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	57	suppressed
Meloxicam	Meloxicam	54	18
Alendronate Sodium	Alendronate Sodium	53	16
Glipizide	Glipizide	53	16
Trazodone Hcl	Trazodone Hcl	53	19
Alprazolam	Alprazolam	52	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	50	15
Bisoprolol Fumarate	Bisoprolol Fumarate	47	13
Furosemide	Furosemide	41	21
Morphine Sulfate Er	Morphine Sulfate	41	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	13
Tramadol Hcl	Tramadol Hcl	40	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	38	14
Clonazepam	Clonazepam	33	suppressed
Potassium Chloride	Potassium Chloride	33	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	23
Temazepam	Temazepam	31	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	29	27
Buspirone Hcl	Buspirone Hcl	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	12
Tamsulosin Hcl	Tamsulosin Hcl	27	suppressed
Azithromycin	Azithromycin	26	24
Metformin Hcl	Metformin Hcl	26	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Estradiol	Estradiol	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Eliquis	Apixaban	21	suppressed
Famotidine	Famotidine	21	suppressed
Prednisone	Prednisone	21	16
Acyclovir	Acyclovir	20	11
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Amoxicillin	Amoxicillin	19	16
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	19	suppressed
Cephalexin	Cephalexin	18	15
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	18	18
Hydrocortisone	Hydrocortisone	18	12
Azelastine Hcl	Azelastine Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	16	16
Metoprolol Succinate	Metoprolol Succinate	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Bupropion Xl	Bupropion Hcl	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Nystatin	Nystatin	13	suppressed
Sertraline Hcl	Sertraline Hcl	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Erythromycin	Erythromycin Base	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Ezetimibe	Ezetimibe	11	suppressed
Lactulose	Lactulose	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error